Cell Research:孙颖浩发现中国人群前列腺癌特异融合基因

2012-04-10 孙颖浩等 Cell Research

孙颖浩教授 前列腺癌发病率在西方国家位于男性恶性肿瘤首位,随着我国社会人口老龄化,该病发病率近年来显著上升。前列腺癌有着明显的种族特异性,然而,产生这种特异性的分子生物学机制至今未明。 第二军医大学长海医院孙颖浩教授运用RNA-seq技术首次对中国人前列腺癌及癌旁组织进行系统研究,发现新型融合基因、癌相关长链非编码RNA、异构体和点突变。研究发现,在欧美人群中普遍高频表达(50-80%)的融合

孙颖浩教授

前列腺癌发病率在西方国家位于男性恶性肿瘤首位,随着我国社会人口老龄化,该病发病率近年来显著上升。前列腺癌有着明显的种族特异性,然而,产生这种特异性的分子生物学机制至今未明。

第二军医大学长海医院孙颖浩教授运用RNA-seq技术首次对中国人前列腺癌及癌旁组织进行系统研究,发现新型融合基因、癌相关长链非编码RNA、异构体和点突变。研究发现,在欧美人群中普遍高频表达(50-80%)的融合基因TMPRSS2-ERG在中国人群中的表达率仅有20%左右,而在欧美人群中尚未发现的融合基因CTAGE5-KHDRBS3和USP9Y-TTTY15在中国人群中却有很高的表达频率,分别为37%和35.2%,提示这些融合基因具有中国人群特异性。相关论文发表在2月21日的《细胞研究》(Cell  Research)杂志上。

研究人员发现多个癌组织差异性表达的长链非编码RNA进行了验证,发现PCA3,FR0348383 和 MALAT-1在癌组织中的过表达率分别为80%,72.5%和82.5%,FR0257520 在癌组织中的低表达率为82.5%。此外,研究者还发现并验证了PSA新型异构体,具有潜在的诊断价值。

研究人员根据此次研究结果绘制了中国人群特异性的前列腺癌图谱,提出了3条关键信号通路,为深入认识中国人群前列腺癌的发生发展机制奠定基础。这些研究成果是第二代测序的成功范例,首次揭示了中国人群前列腺癌的全貌,新研究为进一步了解前列腺癌的诊断、发病演化机制和种族差异性提供了新线索。(生物谷 bioon.com)

doi:10.1038/cr.2012.30
PMC:
PMID:

RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings

Shancheng Ren, Zhiyu Peng, Jian-Hua Mao, Yongwei Yu, Changjun Yin, Xin Gao, Zilian Cui, Jibin Zhang, Kang Yi, Weidong Xu, Chao Chen, Fubo Wang, Xinwu Guo, Ji Lu, Jun Yang, Min Wei, Zhijian Tian, Yinghui Guan, Liang Tang, Chuanliang Xu, Linhui Wang, Xu Gao, Wei Tian, Jian Wang, Huanming Yang, Jun Wang and Yinghao Sun

There are remarkable disparities among patients of different races with prostate cancer; however, the mechanism underlying this difference remains unclear. Here, we present a comprehensive landscape of the transcriptome profiles of 14 primary prostate cancers and their paired normal counterparts from the Chinese population using RNA-seq, revealing tremendous diversity across prostate cancer transcriptomes with respect to gene fusions, long noncoding RNAs (long ncRNA), alternative splicing and somatic mutations. Three of the 14 tumors (21.4%) harbored a TMPRSS2-ERG fusion, and the low prevalence of this fusion in Chinese patients was further confirmed in an additional tumor set (10/54=18.5%). Notably, two novel gene fusions, CTAGE5-KHDRBS3 (20/54=37%) and USP9Y-TTTY15 (19/54=35.2%), occurred frequently in our patient cohort. Further systematic transcriptional profiling identified numerous long ncRNAs that were differentially expressed in the tumors. An analysis of the correlation between expression of long ncRNA and genes suggested that long ncRNAs may have functions beyond transcriptional regulation. This study yielded new insights into the pathogenesis of prostate cancer in the Chinese population.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022431, encodeId=2437202243152, content=<a href='/topic/show?id=e074453e81e' target=_blank style='color:#2F92EE;'>#孙颖浩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45378, encryptionId=e074453e81e, topicName=孙颖浩)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Jul 19 01:44:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868477, encodeId=068c18684e7e7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 30 13:44:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958691, encodeId=7ee619586918c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 17 04:44:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525350, encodeId=c6e0152535041, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542612, encodeId=1bd61542612eb, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557701, encodeId=28b6155e70106, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022431, encodeId=2437202243152, content=<a href='/topic/show?id=e074453e81e' target=_blank style='color:#2F92EE;'>#孙颖浩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45378, encryptionId=e074453e81e, topicName=孙颖浩)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Jul 19 01:44:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868477, encodeId=068c18684e7e7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 30 13:44:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958691, encodeId=7ee619586918c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 17 04:44:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525350, encodeId=c6e0152535041, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542612, encodeId=1bd61542612eb, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557701, encodeId=28b6155e70106, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022431, encodeId=2437202243152, content=<a href='/topic/show?id=e074453e81e' target=_blank style='color:#2F92EE;'>#孙颖浩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45378, encryptionId=e074453e81e, topicName=孙颖浩)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Jul 19 01:44:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868477, encodeId=068c18684e7e7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 30 13:44:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958691, encodeId=7ee619586918c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 17 04:44:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525350, encodeId=c6e0152535041, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542612, encodeId=1bd61542612eb, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557701, encodeId=28b6155e70106, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2013-01-17 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022431, encodeId=2437202243152, content=<a href='/topic/show?id=e074453e81e' target=_blank style='color:#2F92EE;'>#孙颖浩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45378, encryptionId=e074453e81e, topicName=孙颖浩)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Jul 19 01:44:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868477, encodeId=068c18684e7e7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 30 13:44:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958691, encodeId=7ee619586918c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 17 04:44:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525350, encodeId=c6e0152535041, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542612, encodeId=1bd61542612eb, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557701, encodeId=28b6155e70106, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-04-12 licz0427
  5. [GetPortalCommentsPageByObjectIdResponse(id=2022431, encodeId=2437202243152, content=<a href='/topic/show?id=e074453e81e' target=_blank style='color:#2F92EE;'>#孙颖浩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45378, encryptionId=e074453e81e, topicName=孙颖浩)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Jul 19 01:44:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868477, encodeId=068c18684e7e7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 30 13:44:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958691, encodeId=7ee619586918c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 17 04:44:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525350, encodeId=c6e0152535041, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542612, encodeId=1bd61542612eb, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557701, encodeId=28b6155e70106, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2022431, encodeId=2437202243152, content=<a href='/topic/show?id=e074453e81e' target=_blank style='color:#2F92EE;'>#孙颖浩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45378, encryptionId=e074453e81e, topicName=孙颖浩)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Thu Jul 19 01:44:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868477, encodeId=068c18684e7e7, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 30 13:44:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958691, encodeId=7ee619586918c, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Jan 17 04:44:00 CST 2013, time=2013-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525350, encodeId=c6e0152535041, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542612, encodeId=1bd61542612eb, content=<a href='/topic/show?id=fcec88861b1' target=_blank style='color:#2F92EE;'>#融合基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88861, encryptionId=fcec88861b1, topicName=融合基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=886613418495, createdName=ms3153534357578991, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557701, encodeId=28b6155e70106, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Thu Apr 12 14:44:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-04-12 yangshch

相关资讯

老年及CKD患者的化疗用药调整

    近年流行病学调查结果表明,50%以上的肿瘤患者为老年人,肿瘤也是老年人群的主要死亡原因。       然而,临床上对老年肿瘤患者预防和治疗措施的应用却远低于平均水平。其中很重要的原因之一,是不少临床医师对药物在老年人中可能出现的独特作用机制及副作用了解较少。       目前,肿瘤治疗的循证医学证据多来

Cancer Cell:科学家发现利用低剂量药物AZA和DAC可重编程癌细胞

阿扎胞苷(azacitidine, AZA)结构式,图片来自维基共享资源。 地西他滨(decitabine, DAC)结构式,图片来自维基共享资源。 利用细胞培养物进行实验,来自约翰霍普金斯大学基梅尔癌症研究中心的研究人员发现两种曾经被认为在人癌症治疗中毒性过强的药物的新用途。这两种药物阿扎胞苷(azacitidine, AZA)和地西他滨(decitabine, DAC)是DNA去甲基化试剂

JTO:10种生物标志物有助于肺癌检测

近日,《胸部肿瘤学杂志》(Journal of Thoracic Oncology)发的一项研究表明,对10种肺癌血清生物标志物进行检查可更准确地判断CT发现的结节,避免侵入性活检和X线随访。 在这项探索性研究中,匹兹堡大学的William L. Bigbee博士及其同事将来自匹兹堡大学癌症研究所乔治亚·库珀肺研究登记系统的“训练集”56例非小细胞肺癌(NSCLC)病例与来自匹兹堡肺筛查研究(P

Cancer Discov.:揭示酶PFKFB4在前列腺癌细胞存活中起关键作用

来自英国癌症研究协会的科学家发现如何阻断一种有助于将葡萄糖转换为能量的关键性酶,从而可能提供一种新方法来杀死前列腺癌细胞。相关研究结果于2012年3月22日发表在Cancer Discovery 期刊上。 对所有细胞来说,葡萄糖是一种重要的能量来源。癌细胞要比正常细胞更加快速地发生分裂,因此它们消耗更多的葡萄糖。但是这也会触发导致DNA损伤的自由基大量积累。 在这项研究中,研究人员发

EMBO J.:新研究工具有助揭示癌细胞维持端粒后备策略

顶端一排图片中每张图片都显示在正常的线虫中发现的6条染色体。相反,在底下两排图片中,每张图片显示出经过基因改造的线虫存在异常融合的染色体。但是这种经过基因改造的线虫在只依赖ALT途径来维持端粒的情形下也能够成功地实现繁殖,这就为人们提供一种有价值的工具来研究ALT途径。图片来自Jan Karlseder和Daniel Lackner。 快速分离的癌细胞非常擅长修补导致正常细胞死亡的损伤,包括端粒

J. Virol.:临床前研究证实病毒可杀死胰腺肿瘤

水泡性口炎病毒(vesicular stomatitis virus,VSV)颗粒的透射电子显微镜显微照片,图片来自维基共享资源。 Copyright ©版权Bioon.com所有,若未得到生物谷授权,请勿转载。 在胰腺导管腺癌(pancreatic ductal adenocarcinoma, PDA)小鼠模式动物中,将病毒注入在肿瘤内阻止一些胰腺肿瘤进一步生长,且能消灭其他胰腺肿